Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 5Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Gallbladder Neoplasms 2Colonic Neoplasms 2Waldenstrom Macroglobulinemia 1Thymoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Nasopharyngeal Carcinoma 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Sunitinib 5pembrolizumab 4Paclitaxel 4Carboplatin 4Radiotherapy 3Cyclophosphamide 3Cisplatin 3selinexor 2lenvatinib 2Taxes 2Ramucirumab 2Octreotide 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Erlotinib Hydrochloride 2Chemoradiotherapy 2zimberelimab 1saracatinib 1regorafenib 1epacadostat 1envafolimab 1belinostat 1avelumab 1atezolizumab 1amrubicin 1alovudine 1TP protocol 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thymoma × MK 2206 × Clear all
NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
647 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡